Titan Pharmaceuticals Inc (TTNP)
7.257
0.00 (0.00%)
USD |
NASDAQ |
Apr 15, 16:00
6.96
-0.30
(-4.10%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.634M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -54.07% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.999 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.91% |
Profile
| Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
| URL | https://www.titanpharm.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 09, 2017 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
| URL | https://www.titanpharm.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 09, 2017 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |